NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Harmony Biosciences reported net revenue growth for Q4 and full year 2023, driven by strong WAKIX sales and clinical development advancements.
Harmony Biosciences reported a strong Q4 2023, with net product revenue of $168.4 million, a 31% increase compared to the same period in 2022. GAAP net income was $26.6 million, or $0.45 per diluted share, while Non-GAAP adjusted net income was $42.8 million, or $0.73 per diluted share. The company is projecting net product revenue between $700 and $720 million for 2024.
- Net product revenue for the quarter was $168.4 million, a 31% increase compared to 2022.
- GAAP net income for the quarter was $26.6 million, or $0.45 per diluted share.
- Non-GAAP adjusted net income was $42.8 million, or $0.73 per diluted share.
- FDA granted priority review for WAKIX in pediatric narcolepsy with a PDUFA date of June 21, 2024.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$168M
Revenue by segment
Harmony Biosciences · $160M total across 1 segment · Q3 2023
- WAKIX Net Product Revenue$160M+36.8%100.0%
Forward guidance
Harmony Biosciences expects full year 2024 net product revenue of $700 million to $720 million.
Tailwinds
- Full year 2024 net product revenue expected to be between $700 million and $720 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro